Experts and Doctors on type 2 diabetes mellitus in Victoria, Australia


Locale: Victoria, Australia
Topic: type 2 diabetes mellitus

Top Publications

  1. Cameron F, Donath S, Baghurst P. Measuring glycaemic variation. Curr Diabetes Rev. 2010;6:17-26 pubmed
    ..Investigators therefore need to be clear about the nature of their enquiry of GV and choose an appropriate metric. ..
  2. Krum H, Skiba M, Gilbert R. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Diabet Med. 2003;20:708-12 pubmed
    ..5 mg/day. ..
  3. Adaji A, Schattner P, Jones K. The use of information technology to enhance diabetes management in primary care: a literature review. Inform Prim Care. 2008;16:229-37 pubmed
    ..IT can be used to improve diabetes care by promoting a productive and informative interaction between the patient and the care team. ..
  4. Graco M, Garrard J, Jasper A. Participation in physical activity: perceptions of women with a previous history of gestational diabetes mellitus. Health Promot J Austr. 2009;20:20-5 pubmed
    ..Awareness of the role of physical activity for the prevention of diabetes was low. Physical activity promotion for women with previous GDM needs to be shaped around the opportunities and constraints identified by this population group. ..
  5. Ekinci E, Thomas G, Thomas D, Johnson C, MacIsaac R, Houlihan C, et al. Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake. Diabetes Care. 2009;32:1398-403 pubmed publisher
    ..By contrast, when there is already a suppressed renin angiotensin aldosterone system under habitual high dietary salt intake, the additional NaCl does not alter the AER response. ..
  6. Bolton K, Segal D, McMillan J, Sanigorski A, Collier G, Walder K. Identification of secreted proteins associated with obesity and type 2 diabetes in Psammomys obesus. Int J Obes (Lond). 2009;33:1153-65 pubmed publisher
    ..Furthermore, a number of candidate genes were identified, in particular, Postn, which may have a role in the development of obesity and type 2 diabetes. ..
  7. Andrikopoulos S. Obesity and type 2 diabetes: slow down!--Can metabolic deceleration protect the islet beta cell from excess nutrient-induced damage?. Mol Cell Endocrinol. 2010;316:140-6 pubmed publisher
    ..Strategies that reduce metabolic flux when beta-cells are exposed to nutrient excess need to be considered when treating Type 2 diabetes. ..
  8. Nguyen T, Wong T, Islam F, Hubbard L, Ajilore O, Haroon E, et al. Evidence of early retinal microvascular changes in patients with type 2 diabetes and depression. Psychosom Med. 2010;72:535-8 pubmed publisher
    ..10). These data show that patients with Type 2 diabetes with major depression have wider retinal arterioles, supporting the concept that depression is associated with early microvascular changes in Type 2 diabetes. ..
  9. Kooptiwut S, Kebede M, Zraika S, Visinoni S, Aston Mourney K, Favaloro J, et al. High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction. J Mol Endocrinol. 2005;35:39-48 pubmed
    ..In conclusion, chronic high glucose-induced increases in AGE can result in islet dysfunction and this is associated with reduced glucokinase levels in a mouse model with susceptibility to islet failure. ..

More Information


  1. Aston Mourney K, Proietto J, Andrikopoulos S. Investigational agents that protect pancreatic islet beta-cells from failure. Expert Opin Investig Drugs. 2005;14:1241-50 pubmed
    ..Evidence will also be presented that the future of drug therapy designed to prevent beta-cell failure should target the formation of advanced glycation end products and alleviate oxidative and endoplasmic reticulum stress. ..
  2. Chen M, McAinch A, Macaulay S, Castelli L, O Brien P, Dixon J, et al. Impaired activation of AMP-kinase and fatty acid oxidation by globular adiponectin in cultured human skeletal muscle of obese type 2 diabetics. J Clin Endocrinol Metab. 2005;90:3665-72 pubmed
    ..These data suggest that reduced activation of AMPK by gAD in obese and obese type 2 diabetic subjects is not caused by reduced adiponectin receptor expression but that aspects downstream of the receptor may inhibit AMPK signaling. ..
  3. Kebede M, Favaloro J, Gunton J, Laybutt D, Shaw M, Wong N, et al. Fructose-1,6-bisphosphatase overexpression in pancreatic beta-cells results in reduced insulin secretion: a new mechanism for fat-induced impairment of beta-cell function. Diabetes. 2008;57:1887-95 pubmed publisher
    ..Taken together, these results suggest that upregulation of FBPase in pancreatic islet beta-cells, as occurs in states of lipid oversupply and type 2 diabetes, contributes to insulin secretory dysfunction. ..
  4. Bolton K, Segal D, McMillan J, Jowett J, Heilbronn L, Abberton K, et al. Decorin is a secreted protein associated with obesity and type 2 diabetes. Int J Obes (Lond). 2008;32:1113-21 pubmed publisher
    ..027 and P=0.001, respectively). Decorin expression in adipose tissue was markedly upregulated in the obese state and may therefore play a role in adipose tissue homeostasis or in pathophysiology associated with obesity. ..
  5. Bozaoglu K, Segal D, Shields K, Cummings N, Curran J, Comuzzie A, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009;94:3085-8 pubmed publisher
    ..This replicated result using a large human sample suggests that chemerin may be involved in the development of the metabolic syndrome. ..
  6. Mahmud M, Mazza D. Preconception care of women with diabetes: a review of current guideline recommendations. BMC Womens Health. 2010;10:5 pubmed publisher
  7. Walder K, Kantham L, McMillan J, Trevaskis J, Kerr L, de Silva A, et al. Tanis: a link between type 2 diabetes and inflammation?. Diabetes. 2002;51:1859-66 pubmed
  8. Naemiratch B, Manderson L. 'Normal, but...': living with type 2 diabetes in Bangkok, Thailand. Chronic Illn. 2008;4:188-98 pubmed publisher
    ..The sustained idea of the normality of the embodied and socially embedded self implied that the disease was under control, ensuring its minimal intrusion into social relationships and practical living. ..
  9. Lappas M, Yee K, Permezel M, Rice G. Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-kappa B and I kappa B kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology. 2005;146:1491-7 pubmed
    ..Control of the IKK-beta/NF-kappa B pathway may therefore provide an alternative therapeutic strategy for regulating aberrant cytokine release and thereby alleviating insulin resistance in type 2 diabetes mellitus. ..
  10. Campbell D, Kladis A, Zhang Y, Jenkins A, Prior D, Yii M, et al. Increased tissue kallikrein levels in type 2 diabetes. Diabetologia. 2010;53:779-85 pubmed
    ..However, our findings do not support a role for the kallikrein-kinin system in mediating the effects of statin therapy on endothelial function. ..